Back to news

Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients

Globe Newswire•16/11/2026•06:00 ET
0

Key Highlights

  • ➤DurAVR THV one-year outcomes will be presented from 100 severe aortic stenosis patients
  • ➤Rishi Puri, MD, PhD, will present the late-breaking data at PCR London Valves
  • ➤Presentation covers clinical and hemodynamic outcomes in patients with small aortic annuli
  • ➤Anteris’ DurAVR THV is a biomimetic, balloon-expandable transcatheter heart valve

Expert Statements

Rishi Puri, MD, PhD, Cleveland Clinic

“One-Year Clinical and Hemodynamic Outcomes of a Novel Biomimetic Balloon-Expandable THV in Small Aortic Annuli”

MINNEAPOLIS and BRISBANE, Australia, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (Nasdaq: AVR; ASX: AVR) today announced that Rishi Puri, MD, PhD, Cleveland Clinic, will present one-year clinical and hemodynamic outcomes for the DurAVR(®) Transcatheter Heart Valve (THV) in a late-breaking session at PCR London Valves, held November 22–24, 2026, in London, United Kingdom.

The presentation will report one-year clinical and hemodynamic outcomes from a pooled cohort of 100 patients with severe aortic stenosis who received the DurAVR THV. The DurAVR THV is a biomimetic, balloon-expandable valve and a new class of transcatheter aortic valve replacement (TAVR).

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in